ADMA Quote, Financials, Valuation and Earnings

Corcept Therapeutics has a net margin of 29.96% compared to ADMA Biologics's net margin of 25.86%. ADMA Biologics's return on equity of 39.59% beat Corcept Therapeutics's return on equity of 25.77%.

ADMA Biologics has a consensus price target of $24.62, signalling upside risk potential of 40.76%. On the other hand Corcept Therapeutics has an analysts' consensus of -- which suggests that it could grow by 47.3%. Given that Corcept Therapeutics has higher upside potential than ADMA Biologics, analysts believe Corcept Therapeutics is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.702, which suggesting that the stock is 29.754% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.513, suggesting its less volatile than the S&P 500 by 48.73%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $119.8M, which are smaller than Corcept Therapeutics quarterly revenues of $182.5M. ADMA Biologics's net income of $35.9M is lower than Corcept Therapeutics's net income of $47.2M. Notably, ADMA Biologics's price-to-earnings ratio is 61.25x while Corcept Therapeutics's PE ratio is 40.36x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.63x versus 9.01x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals has a net margin of 29.96% compared to ADMA Biologics's net margin of 34.1%. ADMA Biologics's return on equity of 39.59% beat Catalyst Pharmaceuticals's return on equity of 27.81%.

ADMA Biologics has a consensus price target of $24.62, signalling upside risk potential of 40.76%. On the other hand Catalyst Pharmaceuticals has an analysts' consensus of $32.25 which suggests that it could grow by 53.06%. Given that Catalyst Pharmaceuticals has higher upside potential than ADMA Biologics, analysts believe Catalyst Pharmaceuticals is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.702, which suggesting that the stock is 29.754% less volatile than S&P 500. In comparison Catalyst Pharmaceuticals has a beta of 0.748, suggesting its less volatile than the S&P 500 by 25.213%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Catalyst Pharmaceuticals pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $119.8M, which are smaller than Catalyst Pharmaceuticals quarterly revenues of $128.7M. ADMA Biologics's net income of $35.9M is lower than Catalyst Pharmaceuticals's net income of $43.9M. Notably, ADMA Biologics's price-to-earnings ratio is 61.25x while Catalyst Pharmaceuticals's PE ratio is 17.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.63x versus 5.52x for Catalyst Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of 29.96% compared to ADMA Biologics's net margin of 7.2%. ADMA Biologics's return on equity of 39.59% beat Sarepta Therapeutics's return on equity of 12.48%.

ADMA Biologics has a consensus price target of $24.62, signalling upside risk potential of 40.76%. On the other hand Sarepta Therapeutics has an analysts' consensus of $185.96 which suggests that it could grow by 53.44%. Given that Sarepta Therapeutics has higher upside potential than ADMA Biologics, analysts believe Sarepta Therapeutics is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.702, which suggesting that the stock is 29.754% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.767, suggesting its less volatile than the S&P 500 by 23.328%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $119.8M, which are smaller than Sarepta Therapeutics quarterly revenues of $467.2M. ADMA Biologics's net income of $35.9M is higher than Sarepta Therapeutics's net income of $33.6M. Notably, ADMA Biologics's price-to-earnings ratio is 61.25x while Sarepta Therapeutics's PE ratio is 78.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.63x versus 7.43x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Stoke Therapeutics has a net margin of 29.96% compared to ADMA Biologics's net margin of -540.05%. ADMA Biologics's return on equity of 39.59% beat Stoke Therapeutics's return on equity of -55.64%.

ADMA Biologics has a consensus price target of $24.62, signalling upside risk potential of 40.76%. On the other hand Stoke Therapeutics has an analysts' consensus of $22.50 which suggests that it could grow by 108.33%. Given that Stoke Therapeutics has higher upside potential than ADMA Biologics, analysts believe Stoke Therapeutics is more attractive than ADMA Biologics.

ADMA Biologics has a beta of 0.702, which suggesting that the stock is 29.754% less volatile than S&P 500. In comparison Stoke Therapeutics has a beta of 0.953, suggesting its less volatile than the S&P 500 by 4.73%.

ADMA Biologics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stoke Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ADMA Biologics pays -- of its earnings as a dividend. Stoke Therapeutics pays out -- of its earnings as a dividend.

ADMA Biologics quarterly revenues are $119.8M, which are larger than Stoke Therapeutics quarterly revenues of $4.9M. ADMA Biologics's net income of $35.9M is higher than Stoke Therapeutics's net income of -$26.4M. Notably, ADMA Biologics's price-to-earnings ratio is 61.25x while Stoke Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ADMA Biologics is 10.63x versus 32.79x for Stoke Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.